Time-dependency of the prognostic effect of carcinoembryonic antigen and p53 protein in colorectal adenocarcinoma

Cancer

Volumn 88, Issue 1, 2000, Pages 35-41

  Díez, Manuel ^a,c   Pollán, Marina ^b   Müguerza, Jose M ^a   Gaspar, Maria J ^a   Duce, Antonio M ^a   Alvarez, María J ^a   Ratia, Tomás ^a   Hernández, Pilar ^a   Ruiz, Antonio ^a   Granell, Javier ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Carcinoembryonic antigen; Colorectal carcinoma; P53 protein; Prognostic factors; Recurrence

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE LEVEL;

EID: 20244383713     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<35::AID-CNCR6>3.3.CO;2-G     Document Type: Article

References (22)

1. Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanism, management and adjuvant therapy. Br J Surg 1994;81:7-19.
2. Casillas S, Pelley RJ, Milsom JW. Adjuvant therapy for colorectal cancer. Dis Colon Rectum 1997;40:977-92.
3. Johnson PG, Allegra CJ. Colorectal cancer biology: clinical implications. Semin Oncol 1995;22:418-32.
4. Strauss G, Kwiatkowski D, Harpole D, Lynch T, Skarin A, Sugarbaker D. Molecular and pathological markers in stage I non-small cell lung cancer. J Clin Oncol 1995;13:1265-79.
5. Bosman F. Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 1995;31A:1216-21.
6. Breslow NE, Day EN. Statistical methods in cancer research. Volume II. The analysis of cohort studies. Lyon, France: IARC Scientific Publications, 1987.
7. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995;14:1707-23.
8. Nakamura T, Tabuchi Y, Nakae S, Ohno M, Saitoh Y. Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labelling index for patients with colorectal carcinoma. Cancer 1996;77:1741-6.
9. Bhatavdekar J, Patel D, Ghosh N, Chikhlikar P, Trivedi T, Suthar T, et al. Coexpression of bcl-2, c-myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 1997;40:785-90.
10. Pignatelli M, Vessey C. Adhesion molecules. Novel molecular tools in tumor pathology. Hum Pathol 1994;25:849-56.
11. Wang JY, Reiping T, Ming J. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994;37:272-7.
12. McCall J, Black R, Rich C, Harvey J, Baker R, Watts J, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994;37:875-81.
13. American Society of Clinical Oncology Tumor Marker Expert Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14:2843-77.
14. Pricolo VE, Finkelstein SD, Hansen K, Cole BF, Kirby IB. Mutated p53 gene is an independent adverse predictor of survival on colon carcinoma. Arch Surg 1997;132:371-5.
15. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, et al. Increased p53 protein content of colorectal tumors correlates with poor survival. Br J Cancer 1992;66:758-64.
16. Díez M, Enriquez JM, Camuñas J, González A, Gutíerrez A, Mugüerza JM, et al. Prediction of recurrence in B-C stages of colorectal cancer by p53 protein nuclear expression in comparison with standard pathological features. Eur J Surg Oncol 1995;21:635-9.
17. Velculescu V, El-Deiry W. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42:858-68.
18. Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
19. Yoshimoto M, Sakamoto G, Ohasshi Y. Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer 1993;72:2993-3001.
20. Smith DR, Yi C, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 1996;74:216-23.
21. Mulder J, Baas IO, Polak MM, Goodman SN, Offerhaus GJA. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995; 71:1257-62.
22. Poller DN, Baxter KJ, Shepherd NA. P53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997;75:87-93.